Nitric oxide (NO) prodrugs such as O(2)-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate (JS-K) are a growing class of promising NO-based therapeutics. Nitric oxide release from the anti-cancer lead compound, JS-K, is proposed to occur through a nucleophilic aromatic substitution by glutathione (GSH) catalyzed by glutathione S-transferase (GST) to form a diazeniumdiolate anion that spontaneously releases NO. In this study, a number of structural analogues of JS-K were synthesized and their chemical and biological properties were compared with those of JS-K. The homopiperazine analogue of JS-K showed anti-cancer activity that is comparable with that of JS-K but with a diminished reactivity towards both GSH and GSH/GST; both the aforementioned compounds displayed no cytotoxic activity towards normal renal epithelial cell line at concentrations where they significantly diminished the proliferation of a panel of renal cancer cell lines. These properties may prove advantageous in the further development of this class of nitric oxide prodrugs as cancer therapeutic agents.
Nitric oxide (NO) prodrugs such as n class="Chemical">O(2)-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate (JS-K) are a growing class of promising NO-based therapeutics. Nitric oxide release from the anti-cancer lead compound, JS-K, is proposed to occur through a nucleophilic aromatic substitution by glutathione (GSH) catalyzed by glutathione S-transferase (GST) to form a diazeniumdiolate anion that spontaneously releases NO. In this study, a number of structural analogues of JS-K were synthesized and their chemical and biological properties were compared with those of JS-K. Thehomopiperazine analogue of JS-K showed anti-cancer activity that is comparable with that of JS-K but with a diminished reactivity towards both GSH and GSH/GST; both the aforementioned compounds displayed no cytotoxic activity towards normal renal epithelial cell line at concentrations where they significantly diminished the proliferation of a panel of renal cancer cell lines. These properties may prove advantageous in the further development of this class of nitric oxide prodrugs as cancer therapeutic agents.
Authors: J E Saavedra; A Srinivasan; C L Bonifant; J Chu; A P Shanklin; J L Flippen-Anderson; W G Rice; J A Turpin; K M Davies; L K Keefer Journal: J Org Chem Date: 2001-05-04 Impact factor: 4.354
Authors: Harinath Chakrapani; Michael M Goodblatt; Vidya Udupi; Swati Malaviya; Paul J Shami; Larry K Keefer; Joseph E Saavedra Journal: Bioorg Med Chem Lett Date: 2008-01-04 Impact factor: 2.823
Authors: Brett M Showalter; Melissa M Reynolds; Carlos A Valdez; Joseph E Saavedra; Keith M Davies; John R Klose; Gwendolyn N Chmurny; Michael L Citro; Joseph J Barchi; Scott I Merz; Mark E Meyerhoff; Larry K Keefer Journal: J Am Chem Soc Date: 2005-10-19 Impact factor: 15.419
Authors: Paul J Shami; Joseph E Saavedra; Challice L Bonifant; Jingxi Chu; Vidya Udupi; Swati Malaviya; Brian I Carr; Siddhartha Kar; Meifeng Wang; Lee Jia; Xinhua Ji; Larry K Keefer Journal: J Med Chem Date: 2006-07-13 Impact factor: 7.446
Authors: Tanyel Kiziltepe; Teru Hideshima; Kenji Ishitsuka; Enrique M Ocio; Noopur Raje; Laurence Catley; Chun-Qi Li; Laura J Trudel; Hiroshi Yasui; Sonia Vallet; Jeffery L Kutok; Dharminder Chauhan; Constantine S Mitsiades; Joseph E Saavedra; Gerald N Wogan; Larry K Keefer; Paul J Shami; Kenneth C Anderson Journal: Blood Date: 2007-03-23 Impact factor: 22.113
Authors: Anna E Maciag; Rahul S Nandurdikar; Sam Y Hong; Harinath Chakrapani; Bhalchandra Diwan; Nicole L Morris; Paul J Shami; Yih-Horng Shiao; Lucy M Anderson; Larry K Keefer; Joseph E Saavedra Journal: J Med Chem Date: 2011-10-28 Impact factor: 7.446
Authors: Claudia Weidensteiner; Wilfried Reichardt; Paul J Shami; Joseph E Saavedra; Larry K Keefer; Brunhilde Baumer; Anna Werres; Robert Jasinski; Nadja Osterberg; Astrid Weyerbrock Journal: Nitric Oxide Date: 2013-01-28 Impact factor: 4.427
Authors: Varun Kumar; Sam Y Hong; Anna E Maciag; Joseph E Saavedra; Douglas H Adamson; Robert K Prud'homme; Larry K Keefer; Harinath Chakrapani Journal: Mol Pharm Date: 2010-02-01 Impact factor: 4.939
Authors: Anna E Maciag; Ryan J Holland; Joseph E Saavedra; Harinath Chakrapani; Paul J Shami; Larry K Keefer Journal: For Immunopathol Dis Therap Date: 2012
Authors: Monika Z Kaczmarek; Ryan J Holland; Stephen A Lavanier; Jami A Troxler; Valentyna I Fesenkova; Charlotte A Hanson; Joan L Cmarik; Joseph E Saavedra; Larry K Keefer; Sandra K Ruscetti Journal: Leuk Res Date: 2013-12-12 Impact factor: 3.156
Authors: Jie Liu; Swati Malavya; Xueqian Wang; Joseph E Saavedra; Larry K Keefer; Erik Tokar; Wei Qu; Michael P Waalkes; Paul J Shami Journal: Genomics Date: 2009-04-05 Impact factor: 5.736